Search 

Medherant is a leading developer of next-generation transdermal drug delivery patches.

Transdermal delivery of drugs from a patch provides better control of the dose than achieved with gels, ointments and creams.  However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch.  Medherant’s TEPI Patch® is formulated with a novel polymer adhesive that is mixed with the drug.

One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch.  The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove.

Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs.  

The Company expects to earn revenues from licensing both its products and its technology for use with specific drugs.

Research and experimental development on biotechnology.